$2.71 Billion in Sales Expected for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) This Quarter

Analysts forecast that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) will announce $2.71 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Regeneron Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $2.55 billion and the highest estimate coming in at $2.83 billion. Regeneron Pharmaceuticals posted sales of $2.53 billion during the same quarter last year, which would indicate a positive year over year growth rate of 7.1%. The business is scheduled to issue its next quarterly earnings report before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full year sales of $11.56 billion for the current fiscal year, with estimates ranging from $10.76 billion to $12.11 billion. For the next year, analysts forecast that the company will post sales of $12.41 billion, with estimates ranging from $10.57 billion to $13.78 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last announced its quarterly earnings results on Friday, February 4th. The biopharmaceutical company reported $23.72 earnings per share for the quarter, topping analysts’ consensus estimates of $18.49 by $5.23. The firm had revenue of $4.95 billion for the quarter, compared to the consensus estimate of $4.49 billion. Regeneron Pharmaceuticals had a return on equity of 55.11% and a net margin of 50.24%. The business’s revenue was up 104.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $8.72 earnings per share.

A number of brokerages have weighed in on REGN. Sanford C. Bernstein raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $660.00 price target on the stock in a research report on Monday, January 3rd. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $605.00 to $632.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 12th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $694.00 target price on the stock in a research report on Monday, January 10th. Barclays upped their target price on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “overweight” rating in a research report on Tuesday, April 12th. Finally, StockNews.com started coverage on Regeneron Pharmaceuticals in a research report on Thursday, March 31st. They issued a “buy” rating on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $724.63.

Shares of NASDAQ REGN opened at $659.11 on Monday. The business’s 50 day moving average price is $674.30 and its two-hundred day moving average price is $641.27. The company has a market cap of $70.88 billion, a PE ratio of 9.14, a price-to-earnings-growth ratio of 1.21 and a beta of 0.21. The company has a quick ratio of 3.07, a current ratio of 3.56 and a debt-to-equity ratio of 0.11. Regeneron Pharmaceuticals has a twelve month low of $478.40 and a twelve month high of $747.42.

In other news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction on Tuesday, February 1st. The stock was sold at an average price of $607.46, for a total value of $607,460.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 1,240 shares of the stock in a transaction on Thursday, April 7th. The shares were sold at an average price of $725.00, for a total value of $899,000.00. Following the completion of the sale, the director now owns 1,082 shares of the company’s stock, valued at $784,450. The disclosure for this sale can be found here. Insiders sold a total of 44,459 shares of company stock valued at $30,177,797 over the last quarter. 11.84% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of REGN. Glassman Wealth Services grew its holdings in Regeneron Pharmaceuticals by 19.5% during the 1st quarter. Glassman Wealth Services now owns 92 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 15 shares during the period. Minot Wealth Management LLC grew its holdings in Regeneron Pharmaceuticals by 3.8% during the 1st quarter. Minot Wealth Management LLC now owns 408 shares of the biopharmaceutical company’s stock worth $285,000 after acquiring an additional 15 shares during the period. Centaurus Financial Inc. grew its holdings in Regeneron Pharmaceuticals by 1.2% during the 3rd quarter. Centaurus Financial Inc. now owns 1,400 shares of the biopharmaceutical company’s stock worth $847,000 after acquiring an additional 16 shares during the period. Stratos Wealth Partners LTD. grew its holdings in Regeneron Pharmaceuticals by 3.1% during the 1st quarter. Stratos Wealth Partners LTD. now owns 535 shares of the biopharmaceutical company’s stock worth $374,000 after acquiring an additional 16 shares during the period. Finally, Pinnacle Wealth Planning Services Inc. grew its stake in shares of Regeneron Pharmaceuticals by 4.1% in the 4th quarter. Pinnacle Wealth Planning Services Inc. now owns 429 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 17 shares during the period. Institutional investors and hedge funds own 82.97% of the company’s stock.

About Regeneron Pharmaceuticals (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.